Announcements Trials
Browse Landscape

Phase

Phase 1 12Phase NA 1Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 76Carcinoma, Non-Small-Cell Lung 73Multiple Myeloma 58Prostatic Neoplasms 57Colorectal Neoplasms 45Leukemia, Myeloid, Acute 43Neoplasms 41Melanoma 35Lymphoma 35Lung Neoplasms 32Ovarian Neoplasms 31Lymphoma, Non-Hodgkin 30Squamous Cell Carcinoma of Head and Neck 29Sarcoma 28Neoplasm Metastasis 27Pancreatic Neoplasms 26Endometrial Neoplasms 25Carcinoma, Hepatocellular 25Hodgkin Disease 23Carcinoma, Renal Cell 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Lymphoma, Large B-Cell, Diffuse 22Leukemia, Lymphocytic, Chronic, B-Cell 22Glioma 22Recurrence 21Urinary Bladder Neoplasms 20Myelodysplastic Syndromes 20Head and Neck Neoplasms 20Esophageal Neoplasms 17Stomach Neoplasms 16

Interventions

pembrolizumab 1adagrasib 1Pemetrexed 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Docetaxel 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Solid Tumors × 30 days × Clear all
NCT07415031 2026-05-15

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Mirati Therapeutics Inc.

Phase 2 Recruiting
170 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡